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Abstract
Background: Early hospital readmission of patients after discharge is a public health problem. One major cause of
hospital readmission is dysfunctions in integrated pathways between community and hospital care that can cause
adverse drug events. Furthermore, the French ENEIS 2 study showed that 1.3% of hospital stays originated from serious
adverse drug events in 2009. Pharmacy-led medication reviews at hospital transitions are an effective means of decreasing
medication discrepancies when conducted at admission or discharge. However, it is difficult to assess the true impact of
pharmacist-led medication reviews in specific high-risk populations, such as pediatric and geriatric populations.
In such a context, it is important to demonstrate the effectiveness of medication reconciliation as part of a standardized
medication review process—in pediatric and elderly populations—on all-cause readmissions in a large randomized
controlled clinical trial.
The aim of this study is to assess the impact of the pharmacist-led medication review on the rate of readmissions and/or
death after hospital discharge and patient treatment satisfaction.
Methods/design: The study is a randomized controlled clinical trial. A total of 1400 hospitalized patients will be
randomized in two groups: (1) the experimental group (group receiving a pharmacist-led medication review) and (2)
the control group (group receiving usual care). The pharmacist-led medication review process includes medication
reconciliation, treatment review and medication liaison service. The primary endpoint will be the rate of readmissions
and/or death at 30 days following initial hospitalization discharge. The secondary endpoints will be the rate of hospital
readmission, the rate of emergency department visits, the rate of mortality, the number of consultations and patient
treatment satisfaction at 30 days following initial hospitalization discharge.
Discussion: A randomized controlled trial provides the most extensive evidence on the impact of pharmacist-led
medication reviews on early hospital readmission for extreme age populations.
Trial registration: Current Controlled Trials, NCT02734017. Registered on 4 May 2016.
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Background
Early hospital readmission of patients after discharge is a
public health problem. One major cause of hospital re-
admission is dysfunctions in integrated pathways
between community and hospital care that can cause
adverse drug events (ADE). An ADE is generally defined
as a side effect (anticipated or unanticipated) of an ad-
ministered medication; it may be due to an adverse drug
reaction or a medication error [1]. Furthermore, the
French ENEIS 2 study showed that 1.3% of hospital stays
originated from serious ADE in 2009 [2]. Data from the
literature show that older patients and children are at
high risk of medication errors specifically at hospital
admission and discharge [3–5].
In accordance with the World Health Organization
(WHO) ("Assuring medication accuracy at transitions in
care”) and French health authorities [6], developing pro-
grams on the securing patients’ medications is crucial
through the course of care [7]. Indeed, transitions
between community and hospital settings are at the
highest risk of medication errors [3].
In this context, the pharmacist-led medication review
may appear to be a way to improve patient safety. The
medication review is a structured, critical examination of a
patient’s medicines; the objective is to reach agreement with
the patient regarding treatment to optimize the impact of
medicines, minimize the number of medication-related
problems and reduce waste [8]. When performed by phar-
macists, this is called a pharmacist-led medication review.
The pharmacist-led medication review has been dem-
onstrated to be an effective strategy to reduce medica-
tion discrepancies at admission and discharge [9, 10].
However, it is difficult to assess the real impact of the
pharmacist-led medication review in specific high-risk
populations, such as pediatric and geriatric populations.
Meta-analysis shows that pharmacist-led medication re-
views have brought substantial reductions in the rate of
readmission [10]. This endpoint is important because the
pharmacist aims to improve reductions in medication
errors as well as the transmission of information to the in-
terfaces of the care system [11]. However, the studies
included have certain limitations: (1) a low level of evi-
dence, (2) the heterogeneity of experimental intervention
(medication reconciliation associated or not with treat-
ment review or medication service liaison) [12–20], (3) a
different delay and different modalities in the endpoint
assessment and (4) only one randomized controlled trial
(RCT) performed in a pediatric population [12–16].
In such a context, it is important to demonstrate the
effectiveness of a pharmacist-led medication review in
high-risk populations (geriatrics and pediatrics) using a
high level of evidence based on a large randomized con-
trolled clinical trial. In our study, we hypothesized that
this pharmacist-led medication review—which consists
of (1) preventing medication errors at transitions (ad-
mission or discharge) through medication reconciliation,
(2) analyzing and revising treatment, (3) informing and
educating patients and (4) coordinating health professio-
nals—may decrease hospital readmissions.
The primary objective of this study is to assess the im-
pact of the pharmacist-led medication review on the rate
of all-cause hospital readmissions and/or all-cause death
at 30 days following initial hospitalization discharge. The
secondary objectives are to assess the impact of the
pharmacists-led medication review on the rate of all-cause
readmission in care units, the rate of emergency depart-
ment visits, the rate of mortality, the number of consulta-
tions post-discharge and patient treatment satisfaction.
Methods/Design
Design
This is a prospective, randomized, controlled and open-
label study comparing two patient care strategies: (1) the
experimental group, receiving a pharmacist-led medica-
tion review; (2) the control group, receiving typical care.
The open procedure is the only possible option because
of the nature of the intervention, which requires that
healthcare workers and participants not be blinded. The
study protocol was designed using the recommendations
of the Consolidated Standard of Reporting Trials (CON-
SORT) statement. The Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) checklist
(Additional file 1) and figure (see Fig. 1) were used to
prepare the study protocol.
Partners
The sponsor of this study is the Assistance Publique-
Hôpitaux de Marseille (AP-HM, France). This work is
supported by institutional grants from the French 2014
National Program of Clinical Research (Programme de
Recherche sur la Performance du Système de Soins). All
details are provided in Table 1.
Recruitment of participants and study setting
The recruitment will be performed in a pediatric depart-
ment and a geriatric and internal medicine department.
The methodological support will be provided by the
Clinical Research Unit (Unité d’Aide Méthodologique à
la Recherche Clinique, AP-HM, France). The central
pharmacy of AP-HM is in charge of overall coordination
of the study and implementation of interventions.
Inclusion and exclusion criteria
The details of the inclusion and exclusion criteria are
provided in Table 2. The main inclusion criteria are (1) a
pediatric patient hospitalized in a multidisciplinary
pediatric care unit or (2) adult patient over 65 years old
hospitalized in a geriatric and internal medicine post-
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emergency care unit where nearly all patients are admit-
ted after an emergency room stay. The main exclusion
criteria are patients whose care requires regularly/pro-
grammed re-hospitalization less than 30 days after
discharge from the initial hospitalization.
Participants will be recruited within 24 h after admis-
sion in the care service. When a new patient is eligible
according to the selection criteria, a participant informa-
tion sheet presenting the objectives of the study as well
as procedures is provided and explained:
– To the adult patient or caregiver in the case of
demented patients (Mini Mental State < 21);
– To the parents in the case of minor patients.
Fig. 1 Template ConcReHosp Study
Table 1 French partners
Pharmacists Center/department
Dr. Stéphane Honoré Coordinating investigator, Pôle
Pharmacie, Public Academic
Teaching Hospital, Marseille
Dr. Pierre Bertault-Peres Pôle Pharmacie, Public Academic
Teaching Hospital, Marseille
Dr. Marie-Anne Estève Pôle Pharmacie, Public Academic
Teaching Hospital, Marseille
M. Pierre Renaudin Pôle Pharmacie, Public Academic
Teaching Hospital, Marseille
Dr. Clémence Tabélé Pôle Pharmacie, Public Academic
Teaching Hospital, Marseille
Dr. Florian Correard Pôle Pharmacie, Public Academic
Teaching Hospital, Marseille
Pediatric specialists
Pr Michel Tsimaratos Multidisciplinary Pediatric Care Unit,
Public Academic Teaching
Hospital, Marseille
Internal medicine geriatric specialists
Pr Patrick Villani Internal Medicine Geriatric Care
Unit, Public Academic Teaching
Hospital, Marseille
Dr Aurélie Daumas Internal Medicine Geriatric Care
Unit, Public Academic Teaching
Hospital, Marseille
Dr Stéphane Gayet Internal Medicine Geriatric Care
Unit, Public Academic Teaching
Hospital, Marseille
Methodologists
Pr Pascal Auquier Public health, Public Academic
Teaching Hospital, Marseille
Dr Karine Baumstarck Clinical Research Unit, Public
Academic Teaching Hospital
Table 2 Selection criteria
Inclusion criteria
- Subject aged under 18 or over 65 years
- Subject hospitalized in the multidisciplinary pediatric care unit or
internal medicine, therapeutics, post-emergency care unit, regardless
of the reason for admission
- Subject with or without any comorbidity
- Living in France
- With national public funded health insurance
Exclusion criteria
- Patients whose care requires regular/programmed re-hospitalization
less than 30 days after discharge from initial hospitalization.
- Vulnerable persons according to French law (pregnant women, adults
under guardianship, persons deprived of liberty)
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To reach the target sample, when a patient is admitted
into the service, the physician performing the clinical
examination of entry reviews the patient's inclusion
criteria and considers whether the patient is eligible for
study. He or she then informs the pharmacist of the study.
Randomization
Computer-generated randomized lists will be drawn up
before the beginning of the study using a permuted
block design under the responsibility of the clinical
research unit (AP-HM). The randomization will be
stratified by center. The patients will be randomized to
the control group or the experimental group using a
computer-generated randomization schedule with a 1:1
allocation ratio. The open-label study is the only option
because of the involvement of the patient in the medica-
tion reconciliation procedure.
Experimental and control interventions
Each patient included in the study will be randomized in
one of the following two groups (see Fig. 2):
Control group
In the control group, the pharmaceutical team is only
involved in dispensing drugs, including standard
pharmaceutical analysis prescription, during the hospital
stay. At admission, the medical staff collects the list of
current medications. At discharge, the medical team
provides a prescription without intervention by the hos-
pital pharmacy team. A report is sent to the community
physician at the end of hospitalization.
Experimental group
Participants in the experimental group receive a
pharmacist-led medication review including the following:
(1) a medical and pharmaceutical admission medication
reconciliation and treatment review, (2) a medical and
pharmaceutical medication reconciliation at discharge and
treatment review and (3) medication liaison service.
Medical and pharmaceutical admission medication
reconciliation and treatment review
Medication reconciliation (MedRec) at admission will be
performed by a pharmacist or a pharmacy resident
within 24 h after patient admission. On Saturdays and
Sundays, admission MedRec will take place the following
Monday morning, and for patients admitted on holidays,
the MedRec will be performed the day after.
The admission MedRec first involves completion of
the medication history, with research into information
about patient treatment. Data from several sources
should be gathered; previous medical and pharma-
ceutical records before admission or information from
the patient him- or herself and/or the family or
Fig. 2 ConcReHosp study - flow of the intervention
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caregivers, the community pharmacist and physician
should be gathered by phone. First, the pharmacist or
a pharmacy resident interviews the patient, and then
the interview is conducted with the community
pharmacist. If there are insufficient data, the pharma-
cist should call the general practitioner or the special-
ist. Based on these data, it is possible to formalize the
complete list of medications taken by the patient
before hospitalization. Then, the list is compared to
the admission prescription. Differences from the ad-
mission prescription are discussed between the
hospital pharmacist and hospital physician. If these
are intentional, the hospital physician is asked to note
the reason in the medical record. In the case of medication
errors, the hospital physician issues a revised prescription.
A pharmacist-led treatment review is systematically
associated with MedRec. It consists of pharmaceutical
analysis of the prescription.
Medical and pharmaceutical medication reconciliation at
discharge and treatment review
The medical and pharmaceutical MedRec at discharge
consists of comparing the medication history to the
hospital discharge prescription to identify possible dis-
crepancies. Differences between medication history and
the hospital discharge prescription are discussed between
the hospital pharmacist and hospital physician. The
differences may be intentional, and if this is the case, the
hospital physician notes the changes in the patient record.
In the case of unintentional discrepancies (medication er-
rors), the hospital physician issues a new prescription.
A pharmacist-led treatment review is systematically
associated with MedRec. It consists of pharmaceutical
analysis of the prescription.
Medication Liaison Service
At discharge, the medication liaison service includes the
following:
– A comprehensive medication history contains the
list of medications that the patient was taking prior
to hospitalization and the list of new medications
with comments, making it possible to understand
the evolution of the treatment.
– Counseling: A session with the patient explaining
the comprehensive medication history, the main
adverse drug reactions, warning signs, biological
monitoring, indications and an indication of the
importance of drug adherence.
– A discharge letter faxed to the community
pharmacist and general practitioner (community
physician). This discharge letter will also present
medications prescribed before and after
hospitalization. Additional comments allow the
community pharmacy and physician to understand
the patient's revised treatment.
Endpoints/Evaluation criteria
Primary endpoints
The primary endpoint is the rate of all-cause hospital re-
admission and/or all-cause death and/or emergency de-
partment visits occurring within 30 days after the
patient discharge from initial hospitalization.
All-cause hospital readmission is defined as an un-
scheduled hospital stay in a medical or surgery depart-
ment or intensive care unit, regardless of the reason for
admission or duration of stay.
Death is defined as an occurrence of death between
discharge and day 30.
Not considered are inpatient services, post-acute care
and rehabilitation (PACR) or nursing homes.
Secondary endpoints
– The rate of all-cause hospital readmission, as defined
in the primary endpoint, within 30 days after the
patient discharge from the initial hospitalization.
– The rate of all-cause emergency department visits
occurring within 30 days after the patient discharge
from the initial hospitalization. This is the proportion
of emergency department visits.
– The rate of all-cause mortality occurring within 30
days after the patient discharge from the initial
hospitalization. This is the proportion of deaths.
– The number of consultations scheduled or not
within 30 days post-hospitalization will be studied.
Consultations are defined as interviews with the
attending physician, a specialist physician or a nurse.
– Patient satisfaction with regards to its drug
treatment will be measured using the standardized
questionnaire “Satisfaction with Medicines
Questionnaire (SatMed-Q®)” [21] validated in French
[22]. It includes 17 items related to 6 different
aspects: effectiveness, adverse effects, ease of use,
patient's general opinion, treatment effect on daily
life, quality of monitoring and information provided
by health professionals. Answers are expressed on a
5-point Likert scale from "Not at all" to "Yes, a lot."
There are six scores and an overall score (0 to 100).
The evaluation will be conducted at 30 days post-
hospitalization during the telephone follow-up.
Follow-up and data collection
The evaluation will be performed at three different time
points: baseline (T1), discharge at the hospital (T2) and
30 days after discharge from the hospital (T3). The study
procedure and date collection are detailed in Table 3
and have been established as per the SPIRIT guidelines.
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A clinical research associate will collect the data with
the clinical pharmacist. They will be obtained from the
analysis of institutional documents of the medication
reconciliation between admission and discharge and
telephone follow-up documents 30 days after discharge.
Data protection
As regards the computerized processing of data relating
to this project, which is intended for health research, it
falls within the scope of legislative requirements, in
particular the law of 9 August 2004, and will directly or
indirectly identify the persons concerned.
Statistical considerations
Sample size, power and statistical methods
The calculation of the required number of subjects was
made from the primary endpoint, i.e., the rate of re-
hospitalization and/or death.
Based on the literature, mainly a recent meta-
analysis including the RCTs working on a pharmacist-
led medication review [11], and data provided by the
medical information service, the expected proportion
of re-hospitalization and/or death in the standard
group is 20% (worst case scenario). To detect a differ-
ence of at least 6% between the two groups (i.e., 14%
re-hospitalization of the experimental group) given a
two-sided significance level of 5% and 80% power,
1300 patients are needed (650 in each group). To
prevent 10% dropout, a total of 1400 subjects should
be included. The recruitment will be open for 18
months, and we expect to recruit about 75 patients
per month.
Data analysis
The major principles of the analysis are reported below.
However, a specific protocol of the analysis will be
provided a second time before the initialization of the
study (validated by the investigator coordinator, the
person responsible for the analysis, and the biostatisti-
cian). The data will be analyzed using SPSS version 17.0
software. Statistical significance is defined as p < 0.05. The
methodology is based on the Consolidated Standards of
Reporting Trials Statement (CONSORT, http:// www.con-
sort-statement.org/consort-statement/) [23].
The full analysis population (including all subjects
who will be randomized and at least evaluated at the
baseline) will be used in the primary analysis, and the
per protocol population (including all subjects who
will be randomized and will not have major protocol
deviations) will be used in the secondary analysis to
assess the robustness of the results. No interim
analysis is planned. Demographic and baseline charac-
teristics will be summarized for the two groups
(‘standard’ and ‘experimental’ groups). Missing data
will not be replaced.
Primary endpoint. The proportions of readmission
and/or death at day 30 will be compared between the
two groups (chi2 test or Fisher’s exact test). Proportions
will be presented with 95% confidence intervals. Logistic
regression will be performed to adjust potential
confounding factors; variables relevant to the models
will be selected based on their clinical interest and/or a
threshold p-value ≤ 0.1 during univariate analysis. The
center will be automatically entered into the model. The
final models expressed the odd ratios and their 95% con-
fidence intervals. The unadjusted analysis will be the
primary analysis, and the adjusted analysis will be the
complementary analysis.
Secondary endpoints. Qualitative variables will be
compared between the two groups using the same pro-
cedure. The number of consultations and satisfaction
scores will be compared between the two groups using
Student’s t test or Mann-Whitney test. Multivariate
approaches (logistic or linear regressions) will be
performed using the same procedure.
Data management and data quality
Quality assurance and control, under the responsibility
of the promoter, will be conducted in accordance with
Good Clinical Practice (decisions of 24 November 2006)
to guarantee the integrity of the data collected and the
protection of patients as well as to respect the protocol
and legislation throughout the entire period of patient
inclusion and follow-up by a clinical researcher
mandated by the sponsor.
The nature and frequency of monitoring are estab-
lished according to the definition of the level of monitor-
ing according to the patient's risk and will depend on
the number of patients included, the rhythm of the
inclusions and the difficulties observed during the study
(procedures validated by the Quality Working Group of
the FHF Promotion, which determines the level of moni-
toring to be carried out according to the risk for the
subject) (OECD Recommendation on the Governance of
Clinical Trials, December 2012).
Table 3 Study procedure
T1 T2 T3
Consent X
Randomization X
Satisfaction X
All-cause hospital readmission X
All-cause emergency department visits X
All-cause mortality X
Consultations X
T1 baseline, T2 discharge at hospital, T3 30 days after discharge hospital
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In this test, the level of monitoring is classified as
"minimal" with a patient risk of type A. This will be to
verify the consents. If one or more consents are not
compliant, files will be monitored randomly.
Ethical aspects, laws and regulations
This study is sponsored by the French Ministry of
Health (PREPS 2014 no. 14–0330). The Assistance
Publique-Hôpitaux de Marseille is the promoter and is
in charge of all the administrative measures. As required
by French law, all patients or their relatives will provide
written informed consent to participate [24]. The French
committees for data handling (CIL) approved the study.
The study has been registered at ClinicalTrials.gov since
March 2016 under the number NCT02734017.
Discussion
To our knowledge, this is the first study to assess the
effectiveness of pharmacist-led medication reviews in
two extreme populations at high risk of medication
errors, i.e., pediatric and geriatric populations. Moreover,
the impact of pharmacist-led medication reviews on all--
cause readmissions is not clear, and to our knowledge,
there are no randomized controlled trials involving a
large number of subjects [11].
In our study, we will evaluate patient satisfaction with
their drug treatments. We hypothesize that a patient
with a more precise explanation of his or her treatment
will be more satisfied. Satisfaction being correlated with
adherence, we believe this may decrease ADE [25].
We will use a randomized, open-label, controlled
design, which is the most appropriate design to demon-
strate the efficacy of pharmacist-led medication reviews
in accordance with an Evidence-Based Medicine
Working Group.
However, some issues related to the content of the
protocol study should be discussed.
The open procedure is justified because the nature of
intervention meant that personnel and participants
could not be blinded. Indeed, the patients and the
pharmacist are players in the intervention effect.
A cluster design should be proposed. Indeed, the
experimental program is applied to the whole center and
may affect all the individuals within it. To conform to
the intervention application and to avoid contamination
within the unit, cluster randomization may be advocated.
However, this design requires the inclusion of several
centers, and we have chosen to restrict the number of
centers; we consider it easier to implement the experi-
mentation in adherent centers, where the pharmacist
teams and medical teams are working together, the best
guarantee of the feasibility of the study. This risks min-
imizing the experimentation effect. Moreover, it is
possible that our trial has less power because the
pharmacist intervenes in both groups. However, it is not
possible that the pharmacist does not intervene in the
controlled group as required by law. Our tests there-
fore evaluate additional activities that have not yet
shown their superiority.
The outcomes will be collected during a telephone
follow-up 30 days after hospital discharge. We will call
patients in the case of a patient who is older than 65 years,
parents in the case of a minor patient or caregivers in the
case of an elderly patient who is not able to consent.
Moreover, if the patient reports a hospitalization or a visit
to the emergency department during the 30 days post-
discharge, a verification will be made by telephone call in
the care unit.
Trials status
At the time of manuscript submission (April 2016), the
status of the trial is “open for participant recruitment.”
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 120 kb)
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